Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMZJUV6)

Drug Name
CSJ117 Drug Info
Synonyms Ecleralimab
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Phase 2 [1]
Chronic obstructive pulmonary disease CA22 Phase 2 [2]
Cross-matching ID
TTD Drug ID
DMZJUV6

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Thymic stromal lymphopoietin (TSLP) TTHMW3T TSLP_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 12 Disease of the respiratory system
Disease Class ICD-11: CA23 Asthma
The Studied Tissue Nasal and bronchial airway
The Studied Disease Asthma [ICD-11:CA23]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Thymic stromal lymphopoietin (TSLP) DTT TSLP 8.89E-01 0.3 0.26
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04410523) A 12-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Study to Assess the Efficacy and Safety of CSJ117, When Added to Existing Asthma Therapy in Patients >= 18 Years of Age With Severe Uncontrolled Asthma. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04882124) A 12-week Randomized, participant-and Investigator-blinded, Placebo-controlled, Parallel Group Study to Explore the Efficacy, Pharmacodynamics, Safety, and Pharmacokinetics of Two Doses of Inhaled CSJ117 in Adults With Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health.
3 TSLP Inhibitors for Asthma: Current Status and Future Prospects. Drugs. 2020 Apr;80(5):449-458.